Turinabol

Turinabol (4-chlorodehydromethyltestosterone) is a synthetic oral anabolic-androgenic steroid developed in the 1960s by Jenapharm, an East German pharmaceutical company. It was created by modifying the structure of methandrostenolone (Dianabol) with a 4-chloro substitution derived from clostebol, producing a compound with a significantly altered pharmacological profile. Turinabol became notorious as the cornerstone of East Germany's state-sponsored doping program (Staatsplan 14.25), which systematically administered the drug to thousands of Olympic athletes from the late 1960s through the 1980s, often without their knowledge. The 4-chloro modification prevents aromatization to estrogen, meaning turinabol does not cause water retention, gynecomastia, or other estrogen-related side effects. This made it particularly attractive for athletes in weight-class sports and those requiring speed, strength, and endurance without visible changes in body mass. Unlike many oral anabolic steroids, turinabol produces slow, steady, lean gains rather than rapid increases in size and strength. It has never been approved for medical use by the FDA or any current Western regulatory body, and it was withdrawn from the market following German reunification and the exposure of the East German doping program. Today it remains one of the most commonly detected substances in anti-doping testing due to the discovery of long-term metabolites detectable for many months after last use.